The tweet was deleted by the author.
But we saved everything 🙂.
Beam Therapeutics has been awarded the Overall CGT Solution of the Year for its alpha-1 antitrypsin deficiency program, BEAM-302.
This recognition comes from the esteemed BioTech Awards, highlighting Beam's innovative contributions to the field. The BEAM-302 program focuses on addressing genetic disorders through precise genetic editing techniques.